Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 1, 2000, Pages 156-163

  Hvidberg, Hanne ^a   Struve, Carsten ^a   Krogfelt, Karen A ^a   Christensen, Nils ^b   Rasmussen, Søren N ^a   Frimodt Møller, Niels ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFUROXIME; GENTAMICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ESCHERICHIA COLI; FEMALE; KIDNEY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PYELONEPHRITIS; URINARY TRACT INFECTION;

EID: 0033988234     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.1.156-163.2000     Document Type: Article

References (39)

1. Andriole, V. T. 1992. Urinary tract infections in the 90s: pathogenesis and management. Infection 20:251-256.
2. Auclair, P., C. Lessard, and M. G. Bergeron. 1988. Renal pharmacokinetic changes of gentamicin during enterococcal pyelonephritis. Antimicrob. Agents Chemother. 32:736-739.
3. Bergeron, G., and Y. Marois. 1986. Benefit from high intrarenal levels of gentamicin in the treatment of Escherichia coli pyelonephritis. Kidney Int. 30:481-487.
4. Bergeron, M. G. 1978. A review of models for the therapy of experimental infections. Scand J. Infect. Dis. 14(Suppl.):189-206.
5. Bergeron, M. G. 1989. Current concepts in treatment of pyelonephritis. Intern. Med. 10:65-84.
6. Bergeron, M. G. 1995. Treatment of pyelonephritis in adults. Med. Clin. N. Am. 75:619-649.
7. Diack, S. L. 1930. The determination of the surface area of the white rat. J. Nutr. 3:289-296.
8. Francois, P. 1991. Traitement des infections de l'appareil urinaire. Ann. Pediatr. 38:557-562.
9. Frimodt-Møller, N., O. Sebbesen, and V. F. Thomsen. 1983. The pneumococcus and the mouse protection test: importance of the lag phase in vivo. Chemotherapy (Basel) 29:128-134.
10. Gerber, A. U. 1988. Comparison of once-daily versus thrice-daily human equivalent dosing of aminoglycosides: basic considerations and experimental approach. J. Drug Dev. 1:17-24.
11. Hagberg, L., U. Jodal, T. K. Korhonen, G. Lidin-Janson, U. Lindberg, and C. Svandborg-Edén. 1981. Adhesion, hemagglutination and virulence of Escherichia coli causing urinary tract infections. Infect. Immun. 31:564-570.
12. Hagberg, L., I. Engberg, R. Freter, J. Lam, S. Oiling, and C. Svanborg-Edén. 1983. Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin. Infect. Immun. 40:273-283.
13. Hagberg, L., R. Hull, S. Hull, S. Falkow, R. Freter, and C. Svanborg Edén. 1983. Contribution of adhesion to bacterial persistence in the mouse urinary tract. Infect. Immun. 40:265-272.
14. Hagberg, L., R. Hull, S. Hull, R. McGhee, M. Michalek, and C. Svanborg Edén. 1984. Difference in susceptibility to gram-negative urinary tract infection between C3H/HeJ and C3H/HeN mice. Infect. Immun. 46:839-844.
15. Hooton, T. M., and W. E. Stamm. 1991. Management of acute uncomplicated urinary tract infection in adults. Med. Clin. N. Am. 75:339-357.
16. Johnson, D. E., R. G. Russell, and J. W. Warren. 1996. Animal models of urinary tract infections, p. 377-405. In H. T. L. Mobley and J. W. Warren (ed.), Urinary tract infections: molecular pathogenesis and clinical management. ASM Press, Washington, D.C.
17. Johnson, J. R. 1991. Virulence factors in Escherichia coli urinary tract infection. Clin. Microhiol. Rev. 4:80-128.
18. Johnson, J. R., and J. C. Manivel. 1991. Vesicoureteral reflux induces renal trauma in a mouse model of ascending, unobstructed pyelonephritis. J. Urol. 145:1306-1311.
19. Johnson, J. R., T. Berggren, and J. C. Manivel. 1992. Histopathologic-microbiologic correlates of invasiveness in a mouse model of ascending unobstructed urinary tract infection. J. Infect. Dis. 165:299-305.
20. Johnson, J. R., T. Berggren, D. S. Newburg, R. H. McCluer, and J. C. Manivel. 1992. Detailed histopathological examination contributes to the assessment of Escherichia coli urovirulence. J. Urol. 147:1160-1166.
21. Kunin, C. M. 1981. Duration of treatment of urinary tract infections. Am. J. Med. 71:849-854.
22. Mabeck, C. E., F. Ørskov, and I. Ørskov. 1971. Escherichia coli and renal involvement in urinary tract infection. Lancet i:1312-1314.
23. Maigaard, S., N. Frimodt-Møller, K. G. Naber, and P. O. Madsen. 1979. Renal lymph and interstitial fluid concentration of co-trimazine: an experimental study in dogs. Infection 7:349-353.
24. McCabe, W. R., and G. G. Jackson. 1965. Treatment of pyelonephritis. N. Engl. J. Med. 272:1037-1044.
25. Meyrier, A., and J. Guibert. 1992. Diagnosis and drug treatment of acute pyelonephritis. Drugs 44:356-367.
26. Mulvey, M. A., Y. S. Lopez-Boado, C. L. Wilson, R. Roth, W. C. Parks, J. Heuser, and S. J. Hultgren. 1998. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282:1494-1497.
27. Naber, K. G. 1996. Optimal management of uncomplicated and complicated urinary tract infections. Med. Microbiol. Lett. 5:372-380.
28. Norrby, S. R. 1990. Short-term treatment of uncomplicated lower urinary tract infections in women. Rev. Infect. Dis. 12:458-467.
29. Ørskov, F., and I. Ørskov. 1984. Serotyping of Escherichia coli. Methods Microbiol. 14:43-112.
30. Ørskov, I., and F. Ørskov. 1985. Escherichia coli in extra-intestinal infections. J. Hyg. Camb. 95:551-575.
31. Sandberg, T., B. Kuijser, G. Linid-Janson, K. Lincoln, F. Ørskov, I. Ørskov, E. Stokland, and C. Svanborg-Edén. 1988. Virulence and Escherichia coli in relation to host factors in women with symptomatic urinary tract infection. J. Clin. Microbiol. 26:1471-1476.
32. Schentag, J. J. 1982. Aminoglycoside pharmacokinetics as a guide to therapy and toxicology: renal tubular transport and intrarenal aminoglycoside distribution, p. 143-168 and 191-222. In A. Whelton and C. N. Harols (ed.), The aminoglycosides. Microbiology, clinical use and toxicology. Marcel Dekker Inc., New York, N.Y.
33. Sharma, S., K. Harjai, and R. Mittal. 1991. Enhanced siderophore production and mouse kidney pathogenicity in Escherichia coli grown in urine. J. Med. Microbiol. 35:325-329.
34. Slack, R. C. B. 1992. Urinary tract infections, p. 407-415. In H. P. Lambert and W. O'Grady (ed.), Antibiotics and chemotherapy. 6th ed. Churchill Livingstone, London, United Kingdom.
35. Sobel, J. D. 1991. Bacterial etiologic agents in the pathogenesis of urinary tract infections. Med. Clin. N. Am. 75:253-273.
36. Stamey, T. A., D. E. Govan, and J. M. Palmer. 1965. The localization and treatment of urinary tract infections: the role of bactericidal urine levels as opposed to serum levels. Medicine 44:1-36.
37. Stamey, T. A., W. R. Fair, M. M. Timothy, M. A. Millar, G. Mihara, and Y. G. Lowery. 1974. Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N. Engl. J. Med. 291:1159-1163.
38. Tulkens, P. M., F. Clercq-Braun, J. Donnez, J. Ibrahim, Z. Kállay, M. Delmee, et al. 1988. Safety and efficacy of aminoglycosides once-a-day: experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease. J. Drug Dev. 1:71-83.
39. Whelton, A., and W. G. Walker. 1974. Intrarenal antibiotic distribution in health and diseases. Kidney Int. 6:131-137.